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S334 Poster Session IIGVHD scores were: PC-1 (n5 5): 660.7; NC-1 (n5 4): 0; NC-2 (n
5 4): 0; TLI/ATS (n5 4): 0.460.8; TLI-FTS/ATS (n5 7): 4.560.9,
with similar patterns in liver. Day 6 target organ accumulation of
H-2Kb+CD4+Foxp3+ Treg was markedly decreased (p\ 0.05) and
H-2Kb+CD8+ cells increased (p \ 0.01) in TLI-FTS/ATS hosts.
In conclusion, shielding from thymic irradiation alone ablates
tolerance after TLI/ATS + BMT, indicating that recurrent thymic
radiation exposure in the non-myeloablative setting enhances rather
than impedes early immune mechanisms leading to transplantation
tolerance in this regimen.We are currently delineating novel thymic
pathways of enhanced immunoregulatory cell selection in thymic-
irradiation-induced transplant tolerance after TLI/ATS + BMT.503
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Murine total Lymphoid Irradiation and rabbit Anti-Thymocyte
Serum (TLI/ATS) non-myeloablative conditioning has been trans-
lated for tolerance induction to facilitate engraftment without lethal
GVHD after allogeneic HSCT.Tolerance is mediated by host IL-4-
induced expansion of donor CD4+Foxp3+ Treg from the unmanipu-
lated graft (Pillai et al, Blood 2009). To delineate mechanisms of
IL-4-dependent donor Treg expansion, wild-type (WT) BALB/c
(H-2d) hosts were given 3 doses ATS + 17 doses (240 cGy each)
TLI and infusion of 50 x 106 bone marrow and 60 x 106 CFSE-la-
beled splenocytes (BMT) from WT or STAT6-/- C57BL/6 (H-2b)
donors. Control WT BALB/c were given 800 cGy single-dose total
body irradiation (TBI) with either 50 x 106 bone marrow alone (neg-
ative control, NC-1) or 50 x 106 bone marrow + 60 x 106 splenocytes
(positive control, PC) from WT C56BL/6 donors. Day 6 H-
2Kb+TCR+CD8+ cell accumulation in spleen, liver and colon were
potently inhibited, and H-2Kb+CD4+Foxp3+ Treg proliferation
maintained, after STAT6-/- donor BMT, indicating that host IL-4
effects on donor Treg proliferation is indirect. By contrast, IL-
4Ra-/- BALB/c hosts receiving TLI/ATS+BMT developed dramatic
lethal acuteGVHD [day 6 colonicGVHDscores: PC (n5 5) 660.8;
NC-1 (n 5 5): 0; WT TLI/ATS (n5 10): 1.3 60.9; IL-4Ra-/-TLI/
ATS (n 5 10): 5.8 61.3]. We delineated 2 subsets of IL-4Ra/
CD124hi cells [CD11b+Gr-1Ghi (M1) and CD11b+Gr-1Gint (M2)]
that dominate the host myeloid compartment in WT hosts at both
day 0 after TLI/ATS and day 6 after TLI/ATS + BMT vs TBI/
ATS or TBI/ATS + BMT (p\ 0.05). Both M1 and M2 subsets are
F4/80negCD115negB220negCD11cnegCD1dhi myeloid derived sup-
pressor cells (MDSC), immature marrow-derived cells which are ab-
lated after lethal or sublethal TBI (p\0.05). H-2Kb-neg M1 and M2
populations sorted from host spleens at day 6 after TLI/ATS +
BMT stimulated H-2Kb+CD4+Foxp3+ Treg but not H-
2Kb+CD4+CD25negFoxp3neg or H-2Kb+CD8+ effector proliferation
in 72-hr CFSE MLR with C57BL/6 splenocyte responders. Day 6
H-2Kb-neg M1 and M2 cells sorted from TLI/ATS + BMT-treated
STAT6-/- or IL-4Ra-/- BALB/c hosts were unable to induce H-
2Kb+CD4+Foxp3+ Treg proliferation in MLR, supporting an IL-4/
STAT6-inducible pathway by which these MDSC gain capacity to
induce Treg proliferation. Using hosts deficient in key IL-4/
STAT6-inducible proteins (Arginase, NOS-2) in MDSC, we are
now delineating the MDSC pathway inducing Treg proliferation
and tolerance after TLI/ATS + BMT.504
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Viral pathogens have been implicated in the pathogenesis of
GVHD. Skin rash due to GVHD resembles herpes simplex virus(HSV)-associated erythema multiforme (EM), in which HSV-in-
fected CD34+ stem cells are stimulated to differentiate into antigen
presenting CD1a+ DCs which reside in the skin epidermis and are
known as Langerhans cells (LC). This differentiation involves
increased E-cadherin expression. HSV-primed LCs present HSV
protein to T-cells and lead to EM.
In this prospective study, we examined (1) HSV-induced CD34+
cell differentiation and (2) Expression of the HSV Pol gene in blood
MNC and tissue samples of allogeneic SCT patients obtained before
and after the transplant. HSV prophylaxis was oral acyclovir. Second
skin biopsy was obtained only from patients who developed a rash
posttransplant. Double immunofluorescent staining and FACS anal-
ysis were used to quantify the expression of the HSV antigen (Pol),
CD34 and differentiation-associated markers (e.g., E-cadherin).
A total of 35 patients were enrolled. Data are available in 27 pa-
tients. Twenty-two (81%) had negative pol, CD34/pol, CD14/pol,
CD11b/pol, CD1a/pol immunostaining in the skin at baseline.
Group I: Twelve patients, 7 male, developed GVHD. In this group,
11 (92%) patients became pol+ and 9 had CD34+/pol+ in the skin.
Nine out of 11 (82%) patients had increased number of CD34+/
Pol+ expressing PBMNCs. Seven out of 11 (64%) and 6 out of 7
(86%) patients had increased CD34+/E-cad+ and CD1a+/Pol+
PBMNCs, respectively. Group II: Six patients (22%), all male, devel-
oped rash but no provenGVHD.Only 2 out of 4 patients (50%) with
non-GVHD rash were pol+ in the skin post-SCT. Level of antigen
expression in this group all decreased post-SCT blood samples.
Group III: Eleven patients, 7 of them female, had no rash post-
SCT and all of them remained pol-negative in blood samples
post-transplant. Four patients (36%) had slight increase in CD34+/
Pol+ expressing PBMNCs compared to baseline. CD34+/E-cad+
cells were noted to be minimally increased in 2 patients (18%) only.
In conclusion, our data suggest that HSV can be reactivated at the
cellular level after allogeneic SCT and appears be associated with the
occurrence of skin GVHD. Differentiated LCs in the skin following
HSV infection of the circulating CD34+ cells may well be part of this
association. Additional studies are warranted to confirm these results
and consider new strategies to prevent GVHD, including perhaps
more intense HSV prophylaxis.505
DOUBLE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) RESULTS IN SUCCESSFUL ENGRAFTMENT OF BONE MAR-
ROW FROM BOTH DONORS WITHOUT GRAFT VERSUS HOST OR GRAFT
VERSUS GRAFT EFFECTS
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We hypothesize that the use of two haploidentical donors, each
targeting a different recipient haplotype, will increase anti- leukemia
activity after double haploidentical SCT.We first established a hap-
loidentical transplantmodel using two different hybridmouse strains
as donor and recipient in the experiments. Lethally irradiated
B6CBAF1 (H2Kb/k) recipients were transplanted with T cell de-
pleted (TCD) bone marrow (BM) from B6D2F1 (H2Kb/d) donors.
Recipient mice harvested at days 28, 42 and 84, showed more than
90%donor cell engraftment, including donor derived lymphopoiesis
and myelopoiesis, without evidence of graft versus host disease.
Subsequently, lethally irradiated B6CBAF1 (H2Kb/k) recipients
were transplanted with TCD-BM from two haploidentical donors
(DH model) including B6SJLF1 (H2Kb/s) (donor 1 - D1) and
B6D2F1 (H2Kb/d) (donor 2 - D2). We observed recipients for 90
days and all mice survived without evidence of GVHD or weight
loss. Analyses of blood collected retro-orbitally at day 90 revealed
that recipients of DH transplants had significantly higher WBC
and neutrophil counts than recipients of SH HSCT from either
D1 orD2 respectively. DH recipients consistently showed successful
engraftment with mixed chimerism in both bone marrow and spleen.
We then explored the effects of low dose T cell infusions (1x105) on
chimerism of donor cells. Low doseT cell infusion from eitherD1 or
D2 did not affect the BM cellularity, but did increase the degree of
dominance of that donor’s cells in the BM and spleen.
Recipients of TCDDH transplants were challengedwith P815 tu-
mor cells. We used B6SJLF1 (D1) + B6CBAF1 (D2)/ B6D2F1
model in tumor experiments. Interestingly, recipients of TCD-DH
